CCM
GILD icon

Credo Capital Management’s Gilead Sciences GILD Stock Holding History

Credo Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$79K Buy
1,055
+45
+4% +$3.13K 0.34% 66
2013
Q3 		$63K Sell
1,010
-162
-14% -$9.68K 0.11% 71
2013
Q2 		$60K Buy
+1,172
New +$61.1K 0.05% 66

Other funds holding GILD

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Credo Capital Management's GILD Position: Q4 2013 in Review

Credo Capital Management increased its Gilead Sciences (GILD) stake by 4.5% in Q4 2013, buying an estimated $3.13K and bringing the position to 1,055 shares worth $79K. The position accounts for 0.34% of the portfolio, ranked #66.

Credo Capital Management first reported a position in GILD in Q2 2013 and has held it in 3 quarters since. 1,099 funds tracked by Wall St. Rank hold GILD as of Q4 2013.

  • Credo Capital Management held 1,055 shares of Gilead Sciences worth $79K as of Q4 2013.
  • Credo Capital Management bought 45 Gilead Sciences shares in Q4 2013, an estimated $3.13K.
  • Gilead Sciences made up 0.34% of Credo Capital Management's portfolio in Q4 2013, its #66 holding.
  • Credo Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 3 quarters since.
  • 1,099 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2013.

Based on Credo Capital Management's 13F filing for Q4 2013, filed 24 Jan 2014.